Analysts Set Seaport Therapeutics, Inc. (NASDAQ:SPTX) Price Target at $38.40

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have received an average rating of “Hold” from the ten research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $38.40.

Several research firms have weighed in on SPTX. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a report on Wednesday, May 27th. UBS Group downgraded shares of Seaport Therapeutics to a “sell” rating in a report on Tuesday, June 9th. Seaport Research Partners set a $50.00 price target on shares of Seaport Therapeutics in a research report on Wednesday, July 15th. Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. Finally, Wolfe Research started coverage on Seaport Therapeutics in a report on Tuesday, July 7th. They issued a “hold” rating on the stock.

Insider Buying and Selling

In other Seaport Therapeutics news, Director Robert J. Hombach bought 13,000 shares of Seaport Therapeutics stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Institutional Trading of Seaport Therapeutics

An institutional investor recently bought a new stake in Seaport Therapeutics stock. TRV GP VI LLC acquired a new stake in Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,061,222 shares of the company’s stock, valued at approximately $44,769,742,000. Seaport Therapeutics accounts for about 19.3% of TRV GP VI LLC’s holdings, making the stock its 2nd largest position. TRV GP VI LLC owned approximately 3.85% of Seaport Therapeutics at the end of the most recent quarter.

Seaport Therapeutics Stock Performance

NASDAQ SPTX opened at $23.71 on Friday. The business’s fifty day moving average is $20.20. The stock has a market cap of $1.27 billion and a price-to-earnings ratio of -1.96. Seaport Therapeutics has a 52 week low of $14.85 and a 52 week high of $24.65.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). As a group, equities research analysts expect that Seaport Therapeutics will post -4.6 earnings per share for the current fiscal year.

About Seaport Therapeutics

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.